Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8396818 | Toxicon | 2013 | 8 Pages |
Abstract
Rates of immune reaction to this product were two orders of magnitude lower than the range (up to 75% for early and 81% for late reactions) historically reported with use of minimally refined whole immunoglobulin products against a variety of infections and envenomations. Lower protein dose, greater purity of the active component, lack of the immunogenic Fc portion of the immunoglobulin molecule, and slow intravenous infusion are likely to be the reason for this. Clinical implications of a safer product include that it can be employed in settings where antivenom was once considered too dangerous to use, such as primary care clinics and remote rural areas.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Leslie Boyer, Janice Degan, Anne-Michelle Ruha, Joanne Mallie, Emmanuelle Mangin, Alejandro Alagón,